Marietta, GA, United States
Marietta, GA, United States

Time filter

Source Type

News Article | April 17, 2017
Site: www.prlog.org

-- Marking one of Lanier Islands most popular events, the In-Water Boast Show returns to the Southern lakeside destination Friday, April 21 through Sunday, April 23. Throughout the event, slips the Sunset Cove and Big Beach docks will be filled with new, top-of-the-line boats. In addition to boats, the 2017 In-Water Boat Show will feature a number of exhibitors and vendors, as well as live music, fun in the sun and games on the sand."For many, the In-Water Boat Show marks the unofficial start of lake season," said Stephanie Orr, VP of Sales & Marketing for the resort. "People who've always dreamed of owning a boat of their own – as well as those looking for an upgrade – flock to our docks. Qualified buyers will have an opportunity to test drive or take part in a demo of some of the boats at the event. To add to the allure of the show and season ahead, we'll have our beach open to sunbathers and waders.  We'll also be premiering our new menu at our beachfront eatery, Sunset Cove Beach Café & Club. And at different points of the event, we'll have a DJ, an open-air concert, and loads of family-friendly fun and games. Of course, the best part is, admission to the In-Water Boat Show is FREE, as are the courtesy slips at our Sunset Cove docks for event guests who arrive by boat*."During the In-Water Boat Show, the Kids Zone at Big Beach will feature bounce houses and a balloon artist (noon - 4pm), as well as fun for the whole family with mini golf, knockerball, beach volleyball, cornhole and appearances by LanierWorld mascot, Bucky the Beaver.Friday, April 21          12 pm - 8 pmSaturday, April 22          12 pm - 8 pm / 3-9 pm Butch & the Buckheads on the Sunset Cove StageSunday, April 23          12 pm - 5 pm / 3-6 pm DJ on the Sunset Cove StageTo learn more about the In-Water Boat Show and other future events at Lanier Islands, please visit www.lanierislands.com Nestled less than 45 miles from downtown Atlanta on the southern-most shoreline of Lake Lanier at the foothills of the scenic Blue Ridge Mountains lies the truly distinctive Lanier Islands. Quickly growing in size, scope, and reputation as one of the Southeast's leading lakeside retreats, the Islands is proud to have been designated a member of the highly esteemed Southern Living Hotel Collection. As the resort's crown jewel, Lake Lanier is one of the United States' most popular man-made lakes, encompassing 38,000 surface acres and 690 miles of shoreline in Northeast Georgia. Legacy Lodge, Villas, and LakeHouses enhance the park's broad assortment of accommodation choices and meeting sites – making it the ideal choice for corporate meetings and company retreats. Popular excursions like the beach-and-boardwalk-themed LanierWorld, Lake Lanier Canopy Tours, horseback riding at the Equestrian Center, and boat rentals from Harbor Landing make the islands a terrific choice for families vacationing or "staycationing"in the South. Tranquility – the Spa and the picturesque 18-hole Lanier Islands Legacy Golf Course are major draws for visitors looking to relax or play, and with more than 20 wedding venues to choose from, the Islands is rapidly gaining favor with brides- and grooms-to-be as a highly sought-after Destination Wedding site. Lanier Islands is steadily securing a solid standing for their unique vision of the future of this luxury retreat, their unswerving dedication to the comfort and enjoyment of their guests, and their signature brand of Southern Hospitality. For more information, visit www.lanierislands.com.


Local Cities and their Citizens are Honored with Special Tributes and Special Savings at Southern Lakeside Destination -- Between can drives during Give Back Thursdays and free admission for active duty military and first respondersto LanierWorld, Lanier Islands has been dedicated to giving back to the community that surrounds and supports the lakeside destination. Equally devoted to continuous improvement of its facilities and services for the enjoyment of its visitors, the Islands has devised a way to take the concept of "community outreach" to an entirely new level with the debut of Community Days during Summer 2017."We want the people of Atlanta and surrounding cities to view us as 'their Islands,'" explained Lanier Islands Chairman of the Board, Virgil Williams. "The closest oceanside destination is about five hours away, so we are proud to offer a scenic getaway with all the bells and whistles that's closer to home. It's the ideal destination for adventure or relaxation. They can spend the day or spend several nights in our LakeHouses, Villas or Legacy Lodge – which has been designated a member of the esteemed Southern Living Hotel Collection. We felt the most impactful way to make our guests truly feel like the Islands is theirs, is to honor them with Community Days – which, over the course of a weekend, pays tribute to the city where they live. The best part is, they'll receive an invitation in the mail that affords them and up to 7 more guests with 50% off our admission to LanierWorld – our beach, boardwalk and waterpark entertainment district!"Citizens of the following cities will want to check their mailboxes in the days leading up to their designated Community Days for details about what to expect and an invitation to save 50% off their LanierWorld admission when visiting on their select weekend. Community Day guests will also receive free front gate access ($15 value).  In addition to significant savings, Community Days will comprise a main street festival feel with fun and games on the beach, community featurettes on the 5-story high HD Spectacular Screen, live entertainment, giveaways, photo opportunities with LanierWorld mascot – Bucky the Beaver and so much more. Best of all, between 1-6 p.m. during Community Days, Lanier Islands will select one lucky Community Day visitor each hour to win a Family Season Pass* to LanierWorld Summer Adventure.May 6-7, 2017  Gainesville, Braselton, Hoschton and Flowery BranchMay 13-14, 2017  Lawrenceville, Dacula, Snellville and LilburnMay 20-21, 2017  Sandy Springs, Vinings and Downtown AtlantaMay 30-31, 2017  Suwanee, Sugar Hill, Buford and CummingJune 5-6, 2017  Roswell, Johns Creek, Peachtree Corners, Norcross and DuluthJune 12-13, 2017  Alpharetta, Milton and parts of RoswellJune 19-20, 2017  Athens, Winder, Jefferson and LoganvilleJune 26-27, 2017  Smyrna, Mableton and DouglasvilleSeptember 9-10, 2017  Dunwoody, Chamblee, Decatur and Druid HillsSeptember 16-17, 2017   Marietta, Kennesaw and WoodstockSeptember 23-24, 2017   Dahlonega, Dawsonville and EllijayTo learn more about Community Days, LanierWorld and other events at Lanier Islands, please visit www.lanierislands.com Nestled less than 45 miles from downtown Atlanta on the southern-most shoreline of Lake Lanier at the foothills of the scenic Blue Ridge Mountains lies the truly distinctive Lanier Islands. Quickly growing in size, scope, and reputation as one of the Southeast's leading lakeside retreats, the Islands is proud to have been designated a member of the highly esteemed Southern Living Hotel Collection. As the resort's crown jewel, Lake Lanier is one of the United States' most popular man-made lakes, encompassing 38,000 surface acres and 690 miles of shoreline in Northeast Georgia. Legacy Lodge, Villas, and LakeHouses enhance the park's broad assortment of accommodation choices and meeting sites – making it the ideal choice for corporate meetings and company retreats. Popular excursions like the beach-and-boardwalk-themed LanierWorld, Lake Lanier Canopy Tours, horseback riding at the Equestrian Center, and boat rentals from Harbor Landing make the islands a terrific choice for families vacationing or "staycationing"in the South. Tranquility – the Spa and the picturesque 18-hole Lanier Islands Legacy Golf Course are major draws for visitors looking to relax or play, and with more than 20 wedding venues to choose from, the Islands is rapidly gaining favor with brides- and grooms-to-be as a highly sought-after Destination Wedding site. Lanier Islands is steadily securing a solid standing for their unique vision of the future of this luxury retreat, their unswerving dedication to the comfort and enjoyment of their guests, and their signature brand of Southern Hospitality. For more information, visit www.lanierislands.com.


The physiological Src proto-oncogene is a protein-tyrosine kinase that plays key roles in cell growth, division, migration, and survival signaling pathways. From the N- to C-terminus, Src contains a unique domain, an SH3 domain, an SH2 domain, a protein-tyrosine kinase domain, and a regulatory tail. The chief phosphorylation sites of human Src include an activating pTyr419 that results from phosphorylation in the kinase domain by an adjacent Src molecule and an inhibitory pTyr530 in the regulatory tail that results from phosphorylation by C-terminal Src kinase (Csk) or Chk (Csk homologous kinase). The oncogenic Rous sarcoma viral protein lacks the equivalent of Tyr530 and is constitutively activated. Inactive Src is stabilized by SH2 and SH3 domains on the rear of the kinase domain where they form an immobilizing and inhibitory clamp. Protein kinases including Src contain hydrophobic regulatory and catalytic spines and collateral shell residues that are required to assemble the active enzyme. In the inactive enzyme, the regulatory spine contains a kink or a discontinuity with a structure that is incompatible with catalysis. The conversion of inactive to active Src is accompanied by electrostatic exchanges involving the breaking and making of distinct sets of kinase domain salt bridges and hydrogen bonds. Src-catalyzed protein phosphorylation requires the participation of two Mg2+ ions. Although nearly all protein kinases possess a common K/E/D/D signature, each enzyme exhibits its unique variations of the protein-kinase reaction template. Bosutinib, dasatinib, and ponatinib are Src/multikinase inhibitors that are approved by the FDA for the treatment of chronic myelogenous leukemia and vandetanib is approved for the treatment of medullary thyroid cancer. The Src and BCR-Abl inhibitors saracatinib and AZD0424, along with the previous four drugs, are in clinical trials for a variety of solid tumors including breast and lung cancers. Both ATP and targeted therapeutic Src protein kinase inhibitors such as dasatinib and ponatinib make hydrophobic contacts with catalytic spine residues and form hydrogen bonds with hinge residues connecting the small and large kinase lobes. ©2015 Elsevier Ltd. All rights reserved.


Groh G.I.,Blue Ridge | Groh G.M.,Blue Ridge
Journal of Shoulder and Elbow Surgery | Year: 2014

Background: Reverse shoulder arthroplasty (RSA) has ushered a new era in shoulder surgery. However, the results of RSA also described the complication rates associated with the procedure as inordinate and a learning curve associated with the incidence of complications. Methods: The records of 112 patients who underwent 114 RSA procedures by the senior author (G.I.G.) were reviewed for complications related to a RSA. Of these, 93 RSA procedures were the primary treatment for the shoulder, and 21 were revisions. Results: The total complication rate for the entire group was 7%. Complications included 3 periprosthetic fractures, 3 hematomas, 1 acromion fracture, and 1 deep infection. The complication rate was 19% in the revision RSA group and 4.3% in the primary RSA group (P ≤ .02). Complication rates in the initial RSA patients in this series did not differ from the final procedures in this series (P = .96). The total reoperation rate was 5.3%, and was 19% in the revision RSA group vs 2.2% in the primary RSA group (P ≤ .02). Conclusion: Complications and reoperations associated with a RSA, although significant, occurred at much lower rate than in previous reports. This series demonstrates a significant difference in complication rates and reoperation rates between primary and revision RSA. Revision RSA complications and reoperations were far more common than in primary RSA procedures. No evidence of a learning curve related to surgical experience was demonstrated in this series. © 2014 Journal of Shoulder and Elbow Surgery Board of Trustees.


Roskoski R.,Blue Ridge
Pharmacological Research | Year: 2014

The human epidermal growth factor receptor (EGFR) family consists of four members that belong to the ErbB lineage of proteins (ErbB1-4). These receptors consist of a glycosylated extracellular domain, a single hydrophobic transmembrane segment, and an intracellular portion with a juxtamembrane segment, a protein kinase domain, and a carboxyterminal tail. Seven ligands bind to EGFR including epidermal growth factor and transforming growth factor α, none bind to ErbB2, two bind to ErbB3, and seven ligands bind to ErbB4. The ErbB proteins function as homo and heterodimers. The heterodimer consisting of ErbB2, which lacks a ligand, and ErbB3, which is kinase impaired, is surprisingly the most robust signaling complex of the ErbB family. Growth factor binding to EGFR induces a large conformational change in the extracellular domain, which leads to the exposure of a dimerization arm in domain II of the extracellular segment. Two ligand-EGFR complexes unite to form a back-to-back dimer in which the ligands are on opposite sides of the aggregate. Following ligand binding, EGFR intracellular kinase domains form an asymmetric homodimer that resembles the heterodimer formed by cyclin and cyclin-dependent kinase. The carboxyterminal lobe of the activator kinase of the dimer interacts with the amino-terminal lobe of the receiver kinase thereby leading to its allosteric stimulation. Downstream ErbB signaling modules include the phosphatidylinositol 3-kinase/Akt (PKB) pathway, the Ras/Raf/MEK/ERK1/2 pathway, and the phospholipase C (PLCγ) pathway. Several malignancies are associated with the mutation or increased expression of members of the ErbB family including lung, breast, stomach, colorectal, head and neck, and pancreatic carcinomas and glioblastoma (a brain tumor). Gefitinib, erlotinib, and afatinib are orally effective protein-kinase targeted quinazoline derivatives that are used in the treatment of ERBB1-mutant lung cancer. Lapatinib is an orally effective quinazoline derivative used in the treatment of ErbB2-overexpressing breast cancer. Trastuzumab, pertuzumab, and ado-trastuzumab emtansine, which are given intravenously, are monoclonal antibodies that target the extracellular domain and are used for the treatment of ErbB2-positive breast cancer; ado-trastuzumab emtansine is an antibody-drug conjugate that delivers a cytotoxic drug to cells overexpressing ErbB2. Cetuximab and panitumumab are monoclonal antibodies that target ErbB1 and are used in the treatment of colorectal cancer. Cancers treated with these targeted drugs eventually become resistant to them. The role of combinations of targeted drugs or targeted drugs with cytotoxic therapies is being explored in an effort to prevent or delay drug resistance in the treatment of these malignancies.© 2013 Elsevier Ltd. All rights reserved.


Roskoski Jr. R.,Blue Ridge
Pharmacological Research | Year: 2013

Anaplastic lymphoma kinase was first described in 1994 as the NPM-ALK fusion protein that is expressed in the majority of anaplastic large-cell lymphomas. ALK is a receptor protein-tyrosine kinase that was more fully characterized in 1997. Physiological ALK participates in embryonic nervous system development, but its expression decreases after birth. ALK is a member of the insulin receptor superfamily and is most closely related to leukocyte tyrosine kinase (Ltk), which is a receptor protein-tyrosine kinase. Twenty different ALK-fusion proteins have been described that result from various chromosomal rearrangements, and they have been implicated in the pathogenesis of several diseases including anaplastic large-cell lymphoma, diffuse large B-cell lymphoma, and inflammatory myofibroblastic tumors. The EML4-ALK fusion protein and four other ALK-fusion proteins play a fundamental role in the development in about 5% of non-small cell lung cancers. The formation of dimers by the amino-terminal portion of the ALK fusion proteins results in the activation of the ALK protein kinase domain that plays a key role in the tumorigenic process. Downstream signaling from ALK fusion proteins involves the Ras/Raf/MEK/ERK1/2 cell proliferation module and the JAK/STAT cell survival pathway. Furthermore, nearly two dozen ALK activating mutations participate in the pathogenesis of childhood neuroblastomas along with ALK overexpression. The occurrence of oncogenic ALK, particularly in non-small cell lung cancer, has generated considerable interest and effort in developing ALK inhibitors. Currently, crizotinib has been approved by the US Food and Drug Administration for the treatment of ALK-positive non-small cell lung cancer along with an approved fluorescence in situ hybridization kit used for the diagnosis of the disease. The emergence of crizotinib drug resistance with a median occurrence at approximately 10 months after the initiation of therapy has stimulated the development of second-generation drugs for the treatment of non-small cell lung cancer and other disorders. About 28% of the cases of crizotinib resistance are related to nearly a dozen different mutations of ALK in the EML4-ALK fusion protein; the other cases of resistance are related to the upregulation of alternative signaling pathways or to undefined mechanisms. It is remarkable that the EML4-ALK fusion protein was discovered in 2007 and crizotinib was approved for the treatment of ALK-positive non-small cell lung cancer in 2011, which is a remarkably short timeframe in the overall scheme of drug discovery. © 2012 Elsevier Ltd.


Groh G.I.,Blue Ridge
Journal of Shoulder and Elbow Surgery | Year: 2010

Background: Aseptic loosening of glenoid components is a common problem associated with total shoulder arthroplasty and one cause for failure. A new cementless fluted glenoid component was developed and has shown excellent bony ingrowth in a canine model. Hypothesis: Clinical utilization of this cementless fluted pegged glenoid component in total shoulder arthroplasty would lower rates of radiolucent lines and aseptic loosening. Materials and methods: Between January 2005 and December 2007, 83 primary shoulder arthroplasties with a minimum of 2 years' follow-up were performed with the uncemented fluted pegged glenoid component. Radiographs and records were reviewed to determine stability and survival of the glenoid component. Results: All cementless fluted pegged glenoid components had survived at the most recent clinical follow-up. Radiographs showed no evidence of component loosening or radiolucent lines. Evidence of fingerlike projections of bone between the flanges of the implant was found in 24 cases (29%). Conclusions: A cementless fluted pegged glenoid component showed excellent initial clinical survival and integration. Further studies regarding continued durability of this component appear warranted. © 2010 Journal of Shoulder and Elbow Surgery Board of Trustees.


Roskoski Jr. R.,Blue Ridge
Pharmacological Research | Year: 2014

The epidermal growth factor receptor (EGFR) family consists of four members that belong to the ErbB lineage of proteins (ErbB1-4). These receptors consist of an extracellular domain, a single hydrophobic transmembrane segment, and an intracellular portion with a juxtamembrane segment, a protein kinase domain, and a carboxyterminal tail. The ErbB proteins function as homo and heterodimers. Growth factor binding to EGFR induces a large conformational change in the extracellular domain. Two ligand-EGFR complexes unite to form a back-to-back dimer in which the ligands are on opposite sides of the aggregate. Following ligand binding, EGFR intracellular kinase domains form an asymmetric dimer. The carboxyterminal lobe of the activator kinase of the dimer interacts with the amino-terminal lobe of the receiver kinase thereby leading to its allosteric stimulation. Several malignancies are associated with the mutation or increased expression of members of the ErbB family including lung, breast, stomach, colorectal, head and neck, and pancreatic carcinomas. Gefitinib, erlotinib, and afatinib are orally effective protein-kinase targeted quinazoline derivatives that are used in the treatment of ERBB1-mutant lung cancer and lapatinib is an orally effective quinazoline derivative used in the treatment of ErbB2-overexpressing breast cancer. Moreover, monoclonal antibodies that target the extracellular domain of ErbB2 are used for the treatment of ErbB2-positive breast cancer and monoclonal antibodies that target ErbB1 and are used for the treatment of colorectal cancer. Cancers treated with these targeted drugs eventually become resistant to them, and a current goal of research is to develop drugs that are effective against drug-resistant tumors. © 2014 Elsevier Ltd.


Coatings, coating compositions and coating suspensions that contain solar reflective and/or shielding components for use in coating substrates such as cellulosic fiberboard construction materials. The coatings may vary in color from pink to red or from yellow to orange depending on which colorant or solar reflective pigment is used or combinations of colorants and solar reflective pigments is used. Methods of making and using the coatings and coating compositions/suspensions are also provided.


Coatings, coating compositions and coating suspensions that contain solar reflective and/or shielding components for use in coating substrates such as cellulosic fiberboard construction materials. The coatings may vary in color from pink to red or from yellow to orange depending on which colorant or solar reflective pigment is used or combinations of colorants and solar reflective pigments is used. Methods of making and using the coatings and coating compositions/suspensions are also provided.

Loading Blue Ridge collaborators
Loading Blue Ridge collaborators